PLK4 Inhibitor RP-1664 Shows Dual Action in Neuroblastoma
In a groundbreaking advance poised to redefine therapeutic strategies against high-risk neuroblastoma, researchers have unveiled the potent efficacy of a novel PLK4 inhibitor, RP-1664, through comprehensive preclinical evaluations. Neuroblastoma, a formidable pediatric...
Read moreDetails

